Detection and Clinical Value of Circulating Tumor Cells as an Assisted Prognostic Marker in Colorectal Cancer Patients

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;1(29):22–40.
   Google Scholar
• Benson AB 3rd, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 2018;16(7):874–901.
   Google Scholar
• Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of colorectal cancer in China (Version 2017). 2017.
   Google Scholar
• Chen WQ, Zheng RS, He J, et al. Cancer incidence and mortality in China, 2013. Cancer Letters. 2017;10:63–71.
   Google Scholar
• Zhong W, Yu Z, Zhan J, et al. Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer. Pathol Oncol Res. 2015;21(1):83–95.24875250
   PubMed Web of Science ®Google Scholar
• He B, Zhang HQ, Xiong SP, et al. Changing patterns of serum CEA and CA199 for evaluating the response to first-line chemotherapy in patients with advanced gastric adenocarcinoma. Asian Pac J Cancer Prev. 2015;16(8):3111–3116.25921105
   PubMedGoogle Scholar
• Guo J, Chen S, Li S, et al. A novel classifier based on three preoperative tumor markers predicting the cancer-specific survival of gastric cancer (CEA, CA19-9 and CA72-4). Oncotarget. 2017;9(4):4814–4822.29435143
   PubMedGoogle Scholar
• Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13(1):58–68.18167340
   PubMed Web of Science ®Google Scholar
• Arigami T, Uneosono Y, Hirata M, et al. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cell. Cancer Sci. 2011;102(5):1019–1024.21251161
   PubMed Web of Science ®Google Scholar
• Cao W, Yang W, Li H, et al. Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer. J Surg Oncol. 2011;103(2):110–115.21259243
   PubMed Web of Science ®Google Scholar
• Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–4224.16857794
   PubMed Web of Science ®Google Scholar
• Ennis RD, Katz AE, de Vries GM, et al. Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptasepolymerase chain reaction assay in patients with early stage prostate carcinoma independence from other pretreatment characteristics. Cancer. 1997;79:2402–2408.9191530
   PubMed Web of Science ®Google Scholar
• de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–6309.18829513
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Muller V, Zgabg L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16(9):2634–2645.20406831
   PubMed Web of Science ®Google Scholar
• Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57(9):1242–1255.21784769
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422.27380959
   PubMed Web of Science ®Google Scholar
• Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70.29155929
   PubMed Web of Science ®Google Scholar
• Elshimali YI, Grody WW. The clinical significance of circulating tumor cells in the peripheral blood. Diagn Mol Pathol. 2006;15(4):187–194.17122646
   PubMedGoogle Scholar
• Qiao YY. Circulating tumor cells and the correlation with metastasis and recurrence of tumor. J Modern Oncol. 2011(19):1877–1880.
   Google Scholar
• Paget JA, Restall IJ, Daneshmand M, et al. Repression of cancer cell senescence by PKCiota. Oncogene. 2012;31(31):3584–3596.22120720
   PubMed Web of Science ®Google Scholar
• Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol. 2011;29(12):1547–1555.21422427
   PubMed Web of Science ®Google Scholar
• Soster M, Juris R, Bonacchi S, et al. Targeted dual-color silica nanoparticles provide univocal identification of micmmetastases in preelinieal models of colorectal cancel. Int J Nanomedicine. 2012;7:4797.22973099
   PubMed Web of Science ®Google Scholar
• Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29(12):1556–1563.21422424
   PubMed Web of Science ®Google Scholar
• Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer. 2011;11:336.21816094
   PubMed Web of Science ®Google Scholar
• Btilke E, Orth K, Gerber PA, et al. Gene expression of circulating turnout cells and its correlation witll tumor stage in breast cancer patients. Eur J Med Res. 2009;14(8):359–363.19666396
   PubMed Web of Science ®Google Scholar
• Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012;61(4):810–817.22277196
   PubMed Web of Science ®Google Scholar
• Matsusaka S, Chin K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci. 2010;101(4):1067–1071.20219073
   PubMed Web of Science ®Google Scholar
• Sun YF, Xu Y, Yang XR, et al. Circulating stem cell- like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57(4):1458–1468.23175471
   PubMed Web of Science ®Google Scholar
• Jatana KR, Balasubramanian P, Lang JC, et al. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results. Arch Otolaryngol Head Neck Surg. 2010;136(12):1274–1279.21173379
   PubMedGoogle Scholar
• Papavasiliou P, Fisher T, Kuhn J, et al. Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Proc (Bayl Univ Med Cent). 2010;23(1):11–14.20157496
   PubMedGoogle Scholar
• Ostenfeld EB, Erichsen R, Iversen LH, et al. of patients with colon and rectal cancer in central and northern Denmark, 1998-2009. Clin Epidemiol. 2011;3(Suppl 1):S27–34.
   PubMedGoogle Scholar
• Somlo G, IJau SK, Frankel P, et al. Multipie biomarker expression on circulating tnlnor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced inflammatory, and stage IV breast cance using a novel detection technology. Breast Cancer Res Treat. 2011;128(1):155–163.21499685
   PubMed Web of Science ®Google Scholar
• Vacante M, Ciuni R, Basile F, et al. The liquid biopsy in the management of colorectal cancer: an overview. Biomedicines. 2020;8(9):308.
   PubMed Web of Science ®Google Scholar